Impact of Chronic Obstructive Pulmonary Disease on Incidence, Microbiology and Outcome of Ventilator-Associated Lower Respiratory Tract Infections.

chronic obstructive pulmonary disease intensive care lower respiratory tract infections mechanical ventilation pneumonia tracheobronchitis ventilator-associated

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
23 Jan 2020
Historique:
received: 03 01 2020
accepted: 18 01 2020
entrez: 26 1 2020
pubmed: 26 1 2020
medline: 26 1 2020
Statut: epublish

Résumé

To determine the impact of chronic obstructive pulmonary disease (COPD) on incidence, microbiology, and outcomes of ventilator-associated lower respiratory tract infections (VA-LRTI). Planned ancillary analysis of TAVeM study, including 2960 consecutive adult patients who received invasive mechanical ventilation (MV) > 48 h. COPD patients (n = 494) were compared to non-COPD patients (n = 2466). The diagnosis of ventilator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP) was based on clinical, radiological and quantitative microbiological criteria. No significant difference was found in VAP (12% versus 13%, p = 0.931), or VAT incidence (13% versus 10%, p = 0.093) between COPD and non-COPD patients. Among patients with VA-LRTI, Escherichia coli and Stenotrophomonas maltophilia were significantly more frequent in COPD patients as compared with non-COPD patients. However, COPD had no significant impact on multidrug-resistant bacteria incidence. Appropriate antibiotic treatment was not significantly associated with progression from VAT to VAP among COPD patients who developed VAT, unlike non-COPD patients. Among COPD patients, patients who developed VAT or VAP had significantly longer MV duration (17 days (9-30) or 15 (8-27) versus 7 (4-12), p < 0.001) and intensive care unit (ICU) length of stay (24 (17-39) or 21 (14-40) versus 12 (8-19), p < 0.001) than patients without VA-LRTI. ICU mortality was also higher in COPD patients who developed VAP (44%), but not VAT(38%), as compared to no VA-LRTI (26%, p = 0.006). These worse outcomes associated with VA-LRTI were similar among non-COPD patients. COPD had no significant impact on incidence or outcomes of patients who developed VAP or VAT.

Identifiants

pubmed: 31979375
pii: microorganisms8020165
doi: 10.3390/microorganisms8020165
pmc: PMC7074722
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

S.N.: MSD, Pfizer, Biomérieux, Gilead (lecture and advisory board). A.R.: MaatPharma (advisory board). Appendix A. Other authors declare that they have no competing interests.

Références

Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Intensive Care Med. 2015 Jan;41(1):34-48
pubmed: 25427866
Am J Respir Crit Care Med. 2013 Jul 15;188(2):220-30
pubmed: 23631814
Crit Care Med. 2006 Dec;34(12):2959-66
pubmed: 17012911
Curr Opin Crit Care. 2014 Oct;20(5):525-31
pubmed: 24999921
Ann Transl Med. 2018 Nov;6(21):418
pubmed: 30581826
Ann Intensive Care. 2013 Apr 12;3(1):10
pubmed: 23587445
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2403-11
pubmed: 26407622
Intensive Care Med. 2013 Sep;39(9):1547-55
pubmed: 23812339
Lancet Respir Med. 2015 Nov;3(11):859-68
pubmed: 26472037
Antimicrob Agents Chemother. 2010 Nov;54(11):4851-63
pubmed: 20733044
Am J Med. 2013 Jun;126(6):542-9
pubmed: 23561632
Infect Control Hosp Epidemiol. 2013 Aug;34(8):800-8
pubmed: 23838220
Crit Care. 2006;10(5):R143
pubmed: 17026755
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1133-9
pubmed: 21852541
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
Am Rev Respir Dis. 1990 Sep;142(3):523-8
pubmed: 2202245
Crit Care. 2014 Feb 12;18(1):R32
pubmed: 24521533
Chest. 2018 Mar;153(3):601-610
pubmed: 28802696
J Crit Care. 2006 Mar;21(1):56-65
pubmed: 16616625
Eur Respir J. 2002 Dec;20(6):1483-9
pubmed: 12503708
Chest. 2011 Mar;139(3):513-518
pubmed: 20724738
Eur Respir J. 2013 Apr;41(4):792-9
pubmed: 23018915
Chest. 2011 Jun;139(6):1354-1360
pubmed: 21393392
Intensive Care Med. 2016 Jul;42(7):1190-2
pubmed: 27080532
Respir Med. 2011 Jul;105(7):1022-9
pubmed: 21435855
Chest. 2005 Sep;128(3):1650-6
pubmed: 16162771

Auteurs

Anahita Rouzé (A)

Centre Hospitalier Universitaire Lille, Critical Care Center, F-59000 Lille, France.

Pauline Boddaert (P)

Centre Hospitalier Universitaire Lille, Critical Care Center, F-59000 Lille, France.
Medicine Faculty, University of Lille, F-59000 Lille, France.

Ignacio Martin-Loeches (I)

Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, St James Street, Dublin 8, D08 NHY1 Dublin, Ireland.
Hospital Clinic, IDIBAPS, Universidad de Barcelona, Ciberes, 08036 Barcelona, Spain.

Pedro Povoa (P)

Nova Medical School, New University of Lisbon, 1099-085 Lisbon, Portugal.

Alejandro Rodriguez (A)

ICU, Hospital Universitari de Tarragona Joan XXIII, 43005 Tarragona, Spain.

Nassima Ramdane (N)

Centre Hospitalier Universitaire Lille, University of Lille, EA 2694-Santé Publique, Epidémiologie et Qualité des Soins, Département de Biostatistiques, F-59000 Lille, France.

Jorge Salluh (J)

Institute for Research and Education, D'Or, Rio de Janeiro 22281-100, Brazil.

Marion Houard (M)

Centre Hospitalier Universitaire Lille, Critical Care Center, F-59000 Lille, France.

Saad Nseir (S)

Centre Hospitalier Universitaire Lille, Critical Care Center, F-59000 Lille, France.
Medicine Faculty, University of Lille, F-59000 Lille, France.

Classifications MeSH